Prothrombin time (PT) is a fundamental laboratory test used to evaluate the extrinsic and common pathways of the coagulation cascade. This assay measures the time, in seconds, for plasma to clot after the addition of tissue factor (thromboplastin) and calcium. The process begins with a blood draw, typically using a light-blue top tube containing sodium citrate, which acts as an anticoagulant by binding calcium. In the laboratory, the sample is centrifuged to isolate platelet-poor plasma. The test specifically assesses the functional activity of clotting factors I (fibrinogen), II (prothrombin), V, VII, and X. Factor VII is unique to the extrinsic pathway, making the PT highly sensitive to deficiencies or inhibitors of this specific factor. One of the most common clinical applications of 85610 is the monitoring of patients on oral anticoagulant therapy, primarily warfarin (Coumadin). Because warfarin inhibits the synthesis of vitamin K-dependent factors (II, VII, IX, and X), it prolongs the PT. To ensure consistency across different laboratories and reagents, the PT result is frequently converted into the International Normalized Ratio (INR). The INR is calculated using the formula: INR = (Patient PT / Mean Normal PT) raised to the power of the International Sensitivity Index (ISI). Beyond medication monitoring, the PT is essential for diagnosing bleeding disorders, assessing liver synthetic function (as the liver produces most coagulation factors), and screening for vitamin K deficiency. It is also a standard component of preoperative testing to evaluate a patient's risk of intraoperative or postoperative hemorrhage. A prolonged PT may indicate liver disease, disseminated intravascular coagulation (DIC), or the presence of circulating anticoagulants or inhibitors.